Phase 3 N=1,453 ACTIV-6: COVID-19 Study of Repurposed Medications - Arm F (Montelukast)
Covid19
Primary: Time to Sustained Recovery in Days — 10; 10 days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=463 Longitudinal Follow up to Assess Biomarkers Predictive of Emphysema Progression in Patients With COPD (Chronic Obstructive Pulmonary Disease)
Pulmonary Disease, Chronic Obstructive · Pulmonary Emphysema
Primary: Absolute Change From Baseline at Week 156 in Adjusted Lung Density (ALD) Based on Percentile Density at 15% (PD15) Adjusted for Lung Volume — -0.27; -3.15; -5.04; -4.74…
Phase 4 N=59 Intravenous Paracetamol in Combination With Caudal Ropivacaine
Postoperative Analgesia
Primary: Postoperative Analgesia Requirement — 23; 25; 24; 21 Participants
N/A N=236 Otoacoustic Emission Suppression Study
Neonatal Hearing Loss
Primary: Otoacoustic Suppression Measure — 1.95; 1.33; 2.48; 0.36 dB - Unitless Difference in dB SPL
Phase 1 N=12 Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)
Leukemia, Lymphocytic · Lymphoblastic Lymphoma · T-cell Lymphoma
Primary: Frequency of Dose Limiting Toxicities of Palbociclib — 1; 0 Participants
Phase 1 N=24 A Study to Understand the Effect of a Study Medicine Called ARV-471 on Dabigatran Etexilate in Healthy Adults
Healthy
Primary: Maximum Observed Plasma Concentration (Cmax) of Total Dabigatran When Dabigatran Etexilate is Administered Alone Versus When Dabigatran Etexilate is Administered With…
N/A N=25 Advanced Bolus Calculator for Type 1 Diabetes (ABC4D)
Type 1 Diabetes
Primary: HbA1c — -5.0; -3.0 mmol/mol — p=0.87
N/A N=301 Nourish: A Digital Health Program to Promote the DASH Eating Plan Among Adults With High Blood Pressure
Hypertension · Health Behavior
Primary: Change in Dietary Intake as Measured by Dietary Approaches to Stop Hypertension (DASH) Score — 0.3; 0.3 score on a scale — p=0.89
N/A N=80 SMYLS: A Self-management Program for Youth Living With Sickle Cell Disease
Sickle Cell Disease
Primary: Rate of Recruitment: Dyads — 2 dyads recruited and enrolled/week
N/A N=93 MEDTRUM A7+ TouchCare Insulin Patch Pump (MedInPS)
Diabetes Mellitus
Primary: Estimation of A1C (%) Based on Average Blood Glucose Measured by Continuous Glucose Sensor on the Last 10 Weeks — 7.345; 7.347 estimated percentage of hemoglobin A1C
N/A N=39 Clinical and Radiological Manifestations of Coxitis in Patients With Ankylosing Spondylitis Treated With Golimumab
Ankylosing Spondylitis · Coxitis
Primary: BASFI (Bath Ankylosing Spodylitis Functionality Index) at 12 Months of Follow-up — 1.0 units on a scale
Phase 3 N=35 Genetic Modulation of Working Memory in Attention Deficit Hyperactivity Disorder (ADHD)
ADHD
Primary: Brain Activation — 0.19; -0.08 Beta weights of contrast — p==0.09
Phase 1 N=4 CLR 131 Combined With Radiation for Head and Neck Cancer
Head and Neck Cancer
Primary: Incidence of Treatment Related Adverse Events — 4; 2; 4; 1 Participants
N/A N=24 Effect of Vibrant Capsule on Gastric Emptying and Antropyloroduodenal Motility in Healthy Volunteers
Gastroparesis
Primary: Gastroduodenal Manometry Measurement — 9.862; 10.38; 10.38; 8.433 motility index units (see Description)
Phase 1 N=17 Study in Subjects With Rheumatoid Arthritis to Evaluate the Effect of a Single Dose of Olokizumab on the Pharmacokinetics of Substrates for CYP1A2, CYP2C9, CYP2C19 and CYP3A4
Rheumatoid Arthritis
Primary: Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Infinity (AUC(0-inf)) for Caffeine, Omeprazole and Midazolam — 38.23; 26.94; 1408; 955.8 h*ng/mL